Ralevski Elizabeth, Ball Samuel, Nich Charla, Limoncelli Diana, Petrakis Ismene
Department of Psychiatry, Yale University School of Medicine, West Haven, Connecticut, USA.
Am J Addict. 2007 Nov-Dec;16(6):443-9. doi: 10.1080/10550490701643336.
Although antisocial and borderline personality disorders frequently co-occur with alcohol dependence and other Axis I disorders, their effect on alcohol use outcomes in context of pharmacotherapy remains unclear. Patients with Major Axis I disorders, including alcohol dependence, and diagnosis of antisocial (ASPD) or borderline personality disorder (BPD) were enrolled in a 12-week medication trial for treatment of their alcohol dependence. Everyone was randomized to one of four cells: naltrexone alone, placebo alone, open label disulfiram and naltrexone, or open label disulfiram and placebo. Outcome measures included scales for alcohol use and craving. Data were analyzed comparing patients with ASPD vs. those without, and patients with BPD vs. those without. Diagnosis of personality disorder did not adversely affect alcohol outcomes, and patients with ASPD or BPD did not have a poorer response to medication than patients without diagnosis of ASPD or BPD. The findings suggest that naltrexone and disulfiram can be safely and effectively used with patients who have comorbid diagnoses of Axis I and Axis II disorders.
尽管反社会型人格障碍和边缘型人格障碍常与酒精依赖及其他轴I障碍共病,但在药物治疗背景下,它们对酒精使用结果的影响仍不明确。患有包括酒精依赖在内的主要轴I障碍且被诊断为反社会型人格障碍(ASPD)或边缘型人格障碍(BPD)的患者参加了一项为期12周的药物试验,以治疗他们的酒精依赖。每个人被随机分配到四个组之一:单独使用纳曲酮、单独使用安慰剂、开放标签的双硫仑和纳曲酮,或开放标签的双硫仑和安慰剂。结果指标包括酒精使用和渴望量表。对有ASPD的患者与无ASPD的患者,以及有BPD的患者与无BPD的患者的数据进行了分析比较。人格障碍的诊断并未对酒精使用结果产生不利影响,且患有ASPD或BPD的患者对药物的反应并不比未诊断出ASPD或BPD的患者差。研究结果表明,纳曲酮和双硫仑可安全有效地用于患有轴I和轴II共病诊断的患者。